H.C. Wainwright analyst Robert Burns raised the firm’s price target on Nuvation Bio to $8 from $5 and keeps a Buy rating on the shares. The analyst says the company’s all-stock acquisition of AnHeart Therapeutics brings in two late-stage oncology assets. These agents represent validated mechanisms of action within precision oncology, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio upgraded to Buy at Jefferies following acquisition of AnHeart
- Nuvation Bio upgraded to Buy from Hold at Jefferies
- Nuvation Bio upgraded to Buy from Neutral at BTIG
- Nuvation Bio Enhances Capabilities with AnHeart Merger Deal
- Nuvation Bio to acquire AnHeart Therapeutics in all-stock transaction
